✦ LIBER ✦

Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas

✍ Scribed by Fabio M. Iwamoto; Teri N. Kreisl; Lyndon Kim; J. Paul Duic; John A. Butman; Paul S. Albert; Howard A. Fine

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 175 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24957

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 trial of single-agent bevacizu

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

✍ Jeffrey J. Raizer; Sean Grimm; Marc C. Chamberlain; M. Kelly Nicholas; James P. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB 👁 1 views

Final report of a phase I/II trial of hy

Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83-02

✍ Maria Werner-Wasik; Charles B. Scott; Diana F. Nelson; Laurie E. Gaspar; Kevin J 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB

## BACKGROUND. Efforts to improve local control and survival by increasing the dose of once-daily radiation therapy beyond 70 Gray (Gy) for patients with malignant gliomas have as yet been unsuccessful. Hyperfractionated radiation therapy (HF) should allow for delivery of a higher total dose witho

Efficacy and safety of the combination o

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden : A multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)

✍ Franck Morschhauser; Nicolas Mounier; Catherine Sebban; Pauline Brice; Phillippe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB